Figure 7.
The Tyrosine 51-mediated interaction regulates syndecan-2-mediated tumorigenic activities. (A) CM were collected from the indicated cells, immunoblotted with anti-syndecan-2 (left) or anti-E-cadherin (right) antibodies, and subjected to RT-PCR. (B) Cells were immunostained with anti-E-cadherin antibody and the results were visualized with Texas Red-conjugated goat anti-rabbit. DAPI was used to stain nuclei (blue). Scale bar, 20 μm. (C) The number of cells were evaluated with MTT assay as described in ‘Materials and Methods’. Data are shown as mean ± S.D. (n = 3), *p < 0.05, **p < 0.01 versus VEC or SDC2. (D) The indicated cells (1 × 105 cells/well) were seeded on soft agar. After 17 days, colonies were stained with 0.005% crystal violet and counted. Data are shown as mean ± S.D. (n = 3); *p < 0.05 versus VEC or SDC2. (E) HT-29 cells stably expressing syndecan-2 were treated with 0, 5, and 50 nM S2-P peptide. At 24 h post-treatment the expression levels of the target mRNAs were analyzed by RT-PCR. GAPDH was used as a control (top). Cells (1 × 105 cells/well) were seeded in soft agar with or without 50 nM S2-P peptide, allowed to grow for 17 days, and the number of viable colonies was counted. Data are shown as mean ± S.D. (n = 3), *p < 0.05 versus VEC or un-treatment S2-P peptide.